Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety and Immunogenicity of CDP1 Compared to Erbitux in Healthy Volunteers
NCT03881787Phase 1Completed
- Sponsor
- Dragonboat Biopharmaceutical
- Start
- Apr 2017
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1 trial of cdp1 in colorectal cancer (CRC) (2 arms), sponsored by Dragonboat Biopharmaceutical. Primary endpoint: Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time up to 22 Days. Started Apr 2017; status: completed.
02
Drugs
cdp1
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03881787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881787.